BRIEF—Octapharma presents new data on personalized use of hemophilia A therapy

Swiss family-owned protein specialist Octapharma has presented new data on Nuwiq (simoctocog alfa) at a congress in Glasgow, UK.

At the congress, clinical and real-world evidence were presented, analyzing different approaches to using pharmacokinetic (PK) data to personalise prophylaxis with Nuwiq.

In one study, an individualised dosing approach enabled over half (57%) of patients to reduce dosing with Nuwiq to twice weekly or less.

The 4th generation hemophilia A treatment was approved in the EU in 2014, and in the USA the following year.